Kornimate/medical-research-clean huggingface dataset:
effect of a hydrogen-peroxide and hyaluronic-acid mouthwash (bmg0703) in the treatment of periodontitis

Conditions: Periodontitis; Bleeding Gum; Pocket, Periodontal

Summary: assessment of the efficacy of bmg0703 in the treatment of periodontitis and control of supragingival plaque, compared to chlorhexidine and a placebo product

the enrolled subjects will be examined and treated by specialized medical personnel. patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home. next, subjects will be divided into three groups: after the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with the test product, active comparator or placebo, with the aid of a dedicated sterile syringe. the application will be repeated after approx. 5 minutes. one bottle of the product (test, comparative or placebo) will then be given to the patient who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week. the subjects will then be re-evaluated after 3 days and after a week. during these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth). patients with allergic reactions or hypersensitivity due to the use of the products will be advised to discontinue the use of the products and seek medical advice.

Eligibility criteria:
inclusion criteria: * presence of periodontitis with pockets between 3 and 7 mm * acceptance of informed consent exclusion criteria: * subjects suffering from hiv * subjects suffering from hepatitis * serious systemic diseases preventing the use of specific dental therapies * acute and/or chronic infectious pathologies * inability to provide consent * use of topical or systemic drugs * inability to follow post-intervention hygiene instructions * smokers

Keywords: periodontitis bleeding gum periodontal pocket
pneumocystis jerovici pneumonia in infants and steroids

Conditions: Pneumonia, Pneumocystis Jerovici

Summary: this is a double-blind randomized controlled trial assessing the efficacy of adjuvant corticosteroids in clinically diagnosed pneumocystis jiroveci pneumonia in infants.

the study aims to determine whether the early administration of adjuvant corticosteroids in addition to high dose oral co-trimoxazole reduces mortality amongst infants aged 2-6 months with vertically acquired hiv and clinically diagnosed pneumocystis jiroveci pneumonia. infants will be randomized to receive either a steroid regime of oral prednisolone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days or placebo.

Eligibility criteria:
inclusion criteria: * consecutive infants with hiv and clinical features of pneumocystis jiroveci pneumonia who require oxygen (oxygen saturations in air \< 90%). * clinical diagnosis of pneumocystis jiroveci pneumonia will be made by one of the study investigators. all infants must be hiv elisa positive or exposed, have an oxygen requirement (saturations on air \< 90%) and have severe respiratory distress and cough. they may also have a low grade fever, clear chest or diffuse signs on auscultation and features suggestive of pneumocystis jiroveci infection on chest radiography. exclusion criteria: * previous known allergy or hypersensitivity or other contraindication to corticosteroids or co-trimoxazole. * previous treatment for suspected pneumocystis jiroveci pneumonia or a delay starting steroids for greater than 24 hours after starting high dose co-trimoxazole. * patients who are not exposed to hiv. * infants with known preexisting active pulmonary or cardiac disease. * patients who do not live within the blantyre district and who are unable to attend follow up at qech. * infants whose parents or guardians refuse consent.

Keywords: pneumocystis jiroveci steroids infants
a survey of factors affecting an early or delayed diagnosis of iga nephropathy

Conditions: IgA Nephropathy

Summary: this is a survey of factors which affect a pathologically defined early or delayed diagnosis of iga nephropathy in guangdong general hospital, guangzhou, china. an early or delayed diagnosis of iga nephropathy is pathologically defined using the recently published oxford classification of iga nephropathy. the factors to be surveyed include health examination including urine test, socioeconomic status of patients including education,etc.


Eligibility criteria:
inclusion criteria: * biopsy-proven iga nephropathy patients in guangdong general hospital, guangzhou,china

Keywords: diagnosis iga nephropathy
biliverdin reductase a in chronic hepatitis c virus infection

Conditions: Hepatitis C, Chronic

Summary: in this project, the investigators aim to study the role of biliverdin reductase a (blvra) in hcv infected patients prior and during/after standard antiviral therapy in association with viral clearance, disease progression and treatment response and in comparison with healthy subjects.

1. to analyze biliverdin reductase (blvra) expression in the liver of hvc infected patients undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus ribavirin combination therapy) and patients with other forms of liver diseases undergoing liver biopsy as controls. 2. to analyze blvra expression in peripheral blood leukocytes (pbl) of therapeutically naïve hcv patients, during/after standard antiviral therapy and healthy controls. 3. to analyze bvlra genetic polymorphisms both in hcv infected patients and healthy controls.

Eligibility criteria:
inclusion criteria: blvra expression study * therapeutically naïve hcv patients undergoing antiviral treatment with peg-interferon plus ribavirin combination therapy blvra genetic polymorphisms study * hcv infected patients prior, during, after or without antiviral therapy exclusion criteria: * co-infection with hav, hbv and hiv * disorders of heme metabolism

Keywords: biliverdin reductase blvra hepatitis c hcv peripheral blood mononuclear cells pbmc liver genetic polymorphisms
complex cad treated with pci with des implantation.

Conditions: Complex Coronary Artery Disease

Summary: complex registry is an investigator-initiated, retrospective, high-volume polish single-center clinical registry enrolling 980 consecutive patients with complex coronary artery lesions treated percutaneously between september 2015 and december 2021. all data were collected prospectively as regards the clinical and technical endpoints. the study aimed to assess the safety and efficacy of new-generation, thin-struts des in patients with complex cad at long-term clinical follow-up. the primary endpoint of the study was the occurrence of tlr during follow-up. secondary endpoints were a procedural success and the occurrence of mace, including all-cause death, mi, or tlr.


Eligibility criteria:
inclusion criteria: * for the inclusion of patients in this study, the complexity of cad was defined as having at least one of the following characteristics: chronic total occlusion (cto), lesion length \>40 mm, severe calcification assessed by angiography or intravascular imaging examination, multivessel pci during the same intervention, or true bifurcation defined as any lesion involving both the main vessel (mv), proximal or distal and the ostium of the side branch (sb) (medina 1,1,1; 1,0,1; or 0,1,1). exclusion criteria: * left main stem * pci treated during index procedure; * cardiogenic shock, * thrombolysis before pci; * 12-month follow-up not available
enhancing the outcome of skills training for people with schizophrenia

Conditions: Schizophrenia

Summary: this study will determine the effectiveness of skills training in people with schizophrenia and the applicability of the acquired skills in the "real world."

people with schizophrenia have a large number of social and symptom management training programs available to them. studies suggest that these training programs are effective, but their generalizability and effectiveness in outpatient settings has not been thoroughly examined. this study will examine the treatment outcomes of a skills training approach in schizophrenic individuals taking antipsychotic medication. participants taking stable doses of risperidone, olanzapine, or quetiapine will be randomly assigned to receive either intensive symptom management and social skills training or group therapy for 12 months. a verbal memory test will be used to stratify the randomization procedure and to control for neurocognitive functioning.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder for \> 5 years * use of stable dose risperidone, olanzapine, or quetiapine for at least 1 month with no planned medication changes * social behavior scale (sbs) score \> 45 * willing and able to provide informed consent exclusion criteria: * intelligence quotient \< 70 * use of more than one antipsychotic medication * use of benzodiazepines, tricyclic antidepressants, or anticholinergic medication commonly used to treat extrapyramidal symptoms * diagnostic and statistical manual (dsm)-iv criteria for alcohol or other substance dependence * history of any traumatic brain injury leading to loss of consciousness for \> 30 minutes * diagnosis of a comorbid medical condition that could interfere with antipsychotic medication treatment or the ability to complete the study

Keywords: psychotic disorders
study of the safety, tolerability, pharmacokinetics and safety of bg00010 (neublastin) in subjects with sciatica.

Conditions: Sciatica

Summary: the primary objective of the study is to evaluate the safety, tolerability, and pharmacokinetic (pk) profile of 3 intravenous (iv) injections of bg00010 given on 2 fixed schedules; weekly and as frequently as every 48 hours (but no more than 3 times per week). secondary objectives of this study in this study population are to explore the repeated-dose immunogenicity of bg00010 and to explore the potential of bg00010 to reduce pain following multiple-dose administration.


Eligibility criteria:
key inclusion criteria: * must have a diagnosis of unilateral sciatica, determined by the investigator and as outlined in the protocol. sciatica symptoms must be present for 3 or more months prior to the screening visit. * must rate their pain at \>/=40 mm on the 100 mm visual analog scale (vas) of the short-form mcgill pain questionnaire (sf-mpq)at the screening and baseline visits. key exclusion criteria: * history of malignancy or clinically relevant allergies and/or cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (not related to sciatica), dermatologic, rheumatic/joint, psychiatric, renal, and/or other major disease. * history of severe pain as judged by the investigator, other than that caused by sciatica during the 3 months prior to screening visit. * signs or symptoms of peripheral neuropathy, other than symptoms of sciatica during the 3 months prior to screening visit. * current generalized myalgia * serum creatinine \>1.5 x upper limit of normal (uln). * history of or positive screening test for hepatitis c infection, hepatitis b infection and/or positive for hepatitis b core antibody or positive for human immunodeficiency virus (hiv) antibody. subjects who are hbsag negative and hbcab positive are allowed to participate if they are positive for hbsab igg (see the centers for disease control and prevention's interpretation of the hepatitis b serology panel). * treatment with any prescription medication and/or over the-counter products such as herbal supplements, unless the dose has been stable for 2 weeks prior to the baseline visit. note: other protocol defined inclusion/exclusion criteria may apply
establishment and clinical validation of new technologies for accurate screening of colorectal cancer based on multi-omics

Conditions: Colorectal Cancer

Summary: background: the current screening techniques for colorectal cancer include colonoscopy, fecal occult blood, and high-risk factor questionnaires. however, the colorectal cancer screening technology that has been widely used at present cannot take into account sensitivity and specificity, and the tumor detection rate is low. the purpose of research: 1. build a new type of population colorectal cancer precision screening technology program; 2. improve the detection rate of colorectal cancer in the population by new methods (compared with the existing domestic advanced technology) by ≥20%, and improve the specificity of colorectal cancer screening by ≥15% without significantly reducing the sensitivity.


Eligibility criteria:
inclusion criteria: age: 40-74 years old exclusion criteria: 1. combine severe disorders to make it unsuitable for colonoscopy 2. combine other tumors 3. mental and behavioral abnormalities do not cooperate with the screener 4. researchers believe that other reasons are not suitable for enrollment

Keywords: colorectal cancer cancer screening colonoscopy apcs hrfq
sp16 inflammatory response inhibition trial

Conditions: Myocardial Infarction; Inflammation

Summary: this study will evaluate the potential benefit of blocking inflammation during a heart attack using an investigational anti-inflammatory medicine called sp16. the study will enroll 10 patients and all 10 patients will receive a standard dose of sp16.

the main hypothesis of this study is that a single subcutaneous administration of sp16 0.2 mg/kg is safe and well tolerated in patients with st segment elevation myocardial infarction (stemi) and associated with a reduction in the acute inflammatory response to stemi, as measured as area-under-the-curve (auc) for c reactive protein (crp), the preferred inflammatory marker for cardiovascular risk prognostication. sp16 will be administered subcutaneously as this route has greater ease of administration than intravenous injection. a single dose administration has been selected based upon pre-clinical data and expected clinical use of sp16.

Eligibility criteria:
in order to be eligible for this study, patients must meet all the 3 criteria: 1. presentation to the hospital with acute stemi defined as chest pain (or equivalent) with an onset within 12 hours and electrocardiogram (ecg) evidence of st segment elevation (\>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new (for intermittent pain lasting more than 12 hours, the time from the when the pain became severe and constant); 2. coronary intervention planned and/or completed within 12 hours of symptom onset, and enrollment in the study within 6 hours of angiogram (max 18 hours from symptom onset) 3. age\>21 years in order to be eligible for this study, patients must meet none of the exclusion criteria. * inability to give informed consent * hemodynamic instability as defined as need for inotropic or vasoactive agents, or need for mechanical support devices (including intra-aortic balloon pump) * pregnancy or breastfeeding * preexisting congestive heart failure (american heart association/american college of cardiology class c-d, new york heart association iii-iv) * preexisting severe left ventricular dysfunction (lvef\<20%) * preexisting severe valvular heart disease * known active infections (acute or chronic) * recent (\ 1 mg/kg of prednisone equivalent\], tumor necrosis factor-alpha blockers, cyclosporine) not including non-steroidal anti-inflammatory drugs (nsaids) or corticosteroids used for intravenous (iv) dye allergy only) * recent (\<14 days) or active use of anti-inflammatory drugs (not including nsaids or corticosteroids used for iv dye allergy only) * known chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus) * known active malignancy of any type, or prior diagnosis in the past 10 years * neutropenia (absolute neutrophil count\<1,800/mm3 \[or \<1,000/mm3 in african american patients\]) * severe impairment in renal function (estimated glomerular filtration rate \<30 ml/kg\*min) * anticipated need for cardiac or major surgery * known allergy to sp16
school lunch salad bars and fruit and vegetable consumption

Conditions: Children, Only; Behavior, Eating; School; Obesity; Food Selection; Food Habits; Diet Modification; Adolescent Behavior

Summary: the investigators propose an efficacy study (i.e., do salad bars work under controlled conditions in naturalistic settings) to test whether introducing salad bars in elementary, middle, and high schools that have never had salad bars affects students' fv consumption and waste during lunch. a cluster randomized controlled trial will test new salad bars against controls for 6 wks, with/without an additional 4-wk marketing phase .


Eligibility criteria:
inclusion criteria: * students enrolled in any grade between grades one and twelve * student id number matches that on a list of randomly selected student id numbers from the population of student enrolled in school * students who elect to receive a hot entree at lunch * students who assent to participate exclusion criteria: * students in detention * students in special education * students in kindergarten * students not in school for any reason (e.g. illness, vacation)

Keywords: children plate waste fruit and vegetable intake school lunch social marketing
evaluate the efficacy and safety of ki1107 in patients whose tg level is not adequately controlled with rosuvastatin calcium monotherapy while ldl-c is properly controlled

Conditions: Dyslipidemias

Summary: to examine variation rate of non-hdl with ki1107 comparison rosuvastatin monotherapy.

study design: randomly assigned to two groups(ki1107 or rosuvastatin monotherpy) after 4 weeks run-in period and prescribed ki1107 or rosuvastatin for 8 weeks.

Eligibility criteria:
inclusion criteria: * screening visit * age: 19-80 * high risk for cardiovascular disease according to ncep apt iii * tg≥130mg/dl and 160mg/dl\>ldl-c≥100mg/dl for subjects who were not taking statins for 4 weeks * 500mg/dl\>tg≥200mg/dl and ldl-c\<110mg/dl for subjects who were taking statins for 4 weeks * baseline visit * 500mg/dl\>tg≥200mg/dl * ldl-c\<110mg/dl * reduction of ldl-c dompairng screening visit exclusion criteria: * the patient has histories of acute artery disease within 3 months * the patient has histories of operation revasculatiation or aneurysm within 6 months * the patient has histories of unexplained myaliga or diagnosed myalgia or rhabdomyolysis * the patient has histories of effectable disease to the procedrue and clinical trial result
music to reduce pain and anxiety in the pediatric emergency department

Conditions: Pain; Distress

Summary: many medical procedures aimed at helping children can cause them pain and distress. if children experience certain levels of pain or distress, it can have long lasting negative effects. the emergency department can be a particularly stressful place for children and their parents. there are also many procedures that children may have in the emergency department that can cause pain and distress. these include procedures such as needle pokes, stitches, or setting a broken bone. two common methods of managing a child's pain in the emergency department are drugs and distraction. drugs are not always practical and may come with unwanted side effects. distraction is often used formally or informally and by parents or the health professionals. one form of distraction involves listening to music. this can lower the child's pain and distress by moving their attention from the painful stimulus, for example a needle poke, to a more pleasant sensation such as familiar children's songs. this study will test whether music is useful to help lower pain and distress for young children (ages 3 to 6 years) who are visiting an emergency department and need an intravenous line. music is safe and pleasant for children. the results from this study could be important for many children receiving medical care.


Eligibility criteria:
inclusion criteria: * children attending the pediatric ed between the ages of 3 and 6 years - undergoing an iv placement * conscious * have sufficient knowledge of the english language to understand and follow instructions and complete the age-appropriate pain assessment exclusion criteria: * children with hearing impairments, developmental disabilities, or sensory impairment to pain (e.g., spina bifida) * children will be excluded at the discretion of the attending staff (e.g., child in critical condition; requires urgent iv placement; or has altered level of consciousness).

Keywords: children undergoing intravenous placement in the pediatric emergency department
evaluation of consuming olive extract on total cholesterol levels

Conditions: Metabolic Syndrome &#X7C; Serum or Plasma &#X7C; Chemistry - Non-Challenge; Overweight

Summary: the main objective of this nutritional intervention is to assess the efficacy of polyphenol-rich capsules on reducing metabolic syndrome traits, mainly cholesterol levels. for this purpose, a double blind, placebo controlled study of 12 weeks will be carried out. the target population is women and men with overweight or obesity. researchers will compare the experimental capsules with placebo capsules, but will be blinded during the intervention and results analyses. only after analysing the parameters, the groups will be revealed.


Eligibility criteria:
inclusion criteria: * bmi between 25 and 35 kg/m2 * total cholesterol levels in peripheral blood above or equal to 200 mg/dl or ldl-cholesterol levels above or equal to 160 mg/dl. * weight stability during the three months prior the start of the study (±5% of variation). * to be able to attend the visits and accomplish with all the indications of the research staff. * to have signed the written informed consent. exclusion criteria: * any alteration of the gastrointestinal system, functional or structural (gastric ulcer, chronic inflammatory diseases, hernia, etc.) * subjects having undergone any surgical operation in th egastrointestinal tract with permanent consequences (i.e. gastroduodenectomy). * subjects following any pharmacological treatment affecting gastric homeostasis. * suffer from any metabolic disease or cancer process. * being allergic to any of the compounds contained in the study capsules. * excessive alcohol ingestion (14 units/day for women, or 20 units/day for men). * women lactating or during pregnancy. * following any cholesterol-lowering treatment. * people with any mental impairment or whose compliance with the study protocol is at risk.

Keywords: polyhpenols from olives metabolic syndrome cholesterol lifestyle
distraction and nitrous oxide for venous puncture

Conditions: Anxiety; Pain; Venous Puncture

Summary: this study will compare the efficiency of the ipad distraction or the administration of nitrous oxide on the anxiety decrease when a peripheral venous catheter is needed in children between 3 and 9 years old.

the study is aiming at demonstrating the efficacy of active distraction by an ipad on the anxiety consequent to venipuncture and insertion of a peripheral vein catheter. the comparator is nitrous oxide in a 50% mixture with oxygen that is routinely used for sedation during procedural pain. however, nitrous oxide has secondary effects particularly on the inhibition of vitamin b12. the primary outcome is anxiety scores. secondary outcomes are pain scores and satisfaction of parents and health providers. all children will have emla cream (mixture prilocaine and lidocaine) applied one hour prior to venous punction. anxiety, pain and satisfaction scores will be recorded at baseline and then within an hour following the venipuncture and insertion of the peripheral vein catheter.

Eligibility criteria:
inclusion criteria: * venous track needed * french mother tongue * age between 3 and 9 years old exclusion criteria: * children with cognitive disorder (autism, metabolic disorders, * children with cerebral-motor disability * children who don't speak french * children with adhd treatment * children with epilepsy * children who present contraindication to the use of nitrous oxide

Keywords: nitrous oxide distraction